UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PERIPHERAL T‐CELL LYMPHOMA: LEVERAGING A LOGIC FOR PD1/PDL‐1 INHIBITORS

Hematological oncology, 2019-06, Vol.37 (S2), p.161-161

O'Connor, O.A.

2019

Volltextzugriff (PDF)

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Annals of oncology, 2022-03, Vol.33 (3), p.288-298

2022

Volltextzugriff (PDF)

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH

Hematological oncology, 2019-06, Vol.37 (S2), p.474-475

2019

Volltextzugriff (PDF)

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

Annals of oncology, 2009-03, Vol.20 (3), p.520-525

2009

Volltextzugriff (PDF)

Apoptosis: from biology to therapeutic targeting

Annals of oncology, 2011-06, Vol.22, p.iv76-iv79

O'Connor, O.A.

2011

Volltextzugriff (PDF)

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH

Hematological oncology, 2019-06, Vol.37 (S2), p.474-475

2019

Volltextzugriff (PDF)

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.182-183

2019

Volltextzugriff (PDF)

SURVIVAL BENEFIT WITH NOVEL AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (PTCL): THE COLUMBIA UNIVERSITY EXPERIENCE

Hematological oncology, 2019-06, Vol.37 (S2), p.472-473

2019

Volltextzugriff (PDF)

CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES

Hematological oncology, 2017-06, Vol.35 (S2), p.250-250

2017

Volltextzugriff (PDF)

UMBRALISIB AND CARFILZOMIB POTENTLY INHIBIT CAP DEPENDENT TRANSLATION IN LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.510-511

2019

Volltextzugriff (PDF)

AZACYTIDINE AND DECITABINE EXHIBIT DIFFERENTIAL EFFECTS ON CYTOTOXICITY AND METHYLATION AND EXHIBIT CLASS SYNERGY WITH HDACI IN MODELS OF PTCL

Hematological oncology, 2017-06, Vol.35 (S2), p.404-404

2017

Volltextzugriff (PDF)

A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)

Hematological oncology, 2019-06, Vol.37 (S2), p.326-326

2019

Volltextzugriff (PDF)

407 POSTER Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies

European journal of cancer supplements, 2008, Vol.6 (12), p.128-128

2008

Volltextzugriff (PDF)

PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)

Hematological oncology, 2019-06, Vol.37 (S2), p.70-70

2019

Volltextzugriff (PDF)

FIRST‐IN‐CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN‐HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY

Hematological oncology, 2019-06, Vol.37 (S2), p.125-126

2019

Volltextzugriff (PDF)

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.93-95

2019

Volltextzugriff (PDF)

TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.178-179

2019

Volltextzugriff (PDF)

RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.281-283

2019

Volltextzugriff (PDF)

Effects of sterilization methods on the physical characteristics of soil: implications for sorption isotherm analyses

Bulletin of environmental contamination and toxicology, 1995-05, Vol.54 (5), p.668-675

1995

Volltextzugriff (PDF)

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.182-183

2019

Volltextzugriff (PDF)

FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL

Hematological oncology, 2017-06, Vol.35 (S2), p.49-51

2017

Volltextzugriff (PDF)

A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Hematological oncology, 2017-06, Vol.35 (S2), p.87-88

2017

Volltextzugriff (PDF)

A PHASE 1 STUDY OF THE ANTI‐CD37 ANTIBODY‐DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS

Hematological oncology, 2017-06, Vol.35 (S2), p.49-49

2017

Volltextzugriff (PDF)

ORAL AZACYTIDINE (AZA) AND ROMIDEPSIN (R) REVEALS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Hematological oncology, 2017-06, Vol.35 (S2), p.274-275

2017

Volltextzugriff (PDF)

Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate (AGS67E) support a high level of CD37 expression in NHL

Hematological oncology, 2017-06, Vol.35 (S2), p.290-291

2017

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(11)
Lymphoma
(11)
Environmental Sciences
(7)
Environmental Sciences & Ecology
(6)
T-Cell Lymphoma
(6)
Biological And Medical Sciences
(5)
Fundamental And Applied Biological Sciences. Psychology
(4)
Humans
(4)
Oncology
(4)
Physical Sciences
(4)
Technology
(4)
Azacytidine
(3)
Bacteria
(3)
Biodegradation
(3)
Biotechnology
(3)
Engineering
(3)
Female
(3)
Lymphocytes B
(3)
Patients
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PERIPHERAL T‐CELL LYMPHOMA: LEVERAGING A LOGIC FOR PD1/PDL‐1 INHIBITORS

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

Apoptosis: from biology to therapeutic targeting

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

SURVIVAL BENEFIT WITH NOVEL AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (PTCL): THE COLUMBIA UNIVERSITY EXPERIENCE

CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES

UMBRALISIB AND CARFILZOMIB POTENTLY INHIBIT CAP DEPENDENT TRANSLATION IN LYMPHOMA

AZACYTIDINE AND DECITABINE EXHIBIT DIFFERENTIAL EFFECTS ON CYTOTOXICITY AND METHYLATION AND EXHIBIT CLASS SYNERGY WITH HDACI IN MODELS OF PTCL

A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)

407 POSTER Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies

PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)

FIRST‐IN‐CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN‐HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY

RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL

Effects of sterilization methods on the physical characteristics of soil: implications for sorption isotherm analyses

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL

A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)

A PHASE 1 STUDY OF THE ANTI‐CD37 ANTIBODY‐DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS

ORAL AZACYTIDINE (AZA) AND ROMIDEPSIN (R) REVEALS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate (AGS67E) support a high level of CD37 expression in NHL

Suchergebnisse filtern